Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers

Documenti analoghi

• Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
  di: Farrar, Gill, et al.
  Pubblicazione: (2019)
• The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol ((18)F) injection in healthy Japanese adult volunteers
  di: Senda, Michio, et al.
  Pubblicazione: (2015)
• Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment
  di: Wolk, David A., et al.
  Pubblicazione: (2018)
• Diagnostic effectiveness of quantitative [(18)F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus
  di: Leinonen, Ville, et al.
  Pubblicazione: (2014)
• Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis
  di: Heurling, Kerstin, et al.
  Pubblicazione: (2015)